What question did this study set out to answer?

The research aims to address the challenges of treating pancreatic ductal adenocarcinoma by developing a probiotic-based bacterial therapy.

Tumor-Selective Treatment of Metastatic Pancreatic Cancer with Engineered Probiotic Therapy

View Full Paper

Ask AI

Bookmark

Authors

Preclinical insights reveal bacterial therapy improves tumor regression in pancreatic cancer, suggesting new treatment avenues.

The research aims to address the challenges of treating pancreatic ductal adenocarcinoma by developing a probiotic-based bacterial therapy.
Developed a probiotic strain of E. coli expressing Theta toxin for tumor-targeted treatment
Used 2D monolayer and tissue-slice screening to identify effective therapies
Administered intratumoral injections in genetically engineered mouse models
Monitored body response to bacterial treatment for safety and systemic effects
Examined histological and flow cytometry results for immune response assessment
Nis-Theta treatment led to complete tumor regression and extended median survival to 35.5 days
Comparative controls showed lower median survival – 12 days for Vehicle and 16.5 days for non-toxic bacteria
Minimal spread of bacteria to healthy tissues with no significant infection symptoms observed
Histology indicated bacterial association with apoptotic tumor cells in both primary and metastatic sites
Modest anti-tumor immune population recruitment was noted, suggesting synergy with immunotherapy

Decker-Farrell et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark